Intralymphatic immunotherapy for mountain cedar pollinosis: A randomized, double-blind, placebo-controlled trial.

CONCLUSION: In this proof-of-concept trial, intralymphatic immunotherapy was well tolerated and reduced the symptoms and medication use associated with allergic rhinoconjunctivitis caused by mountain cedar pollen. PMID: 32407947 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32407947?dopt=Abstract

Source: Annals of Allergy, Asthma and Immunology - May 10, 2020 Category: Allergy & Immunology Authors: Thompson C, Silvers S, Shapiro M Tags: Ann Allergy Asthma Immunol Source Type: research